<DOC>
	<DOC>NCT01854996</DOC>
	<brief_summary>This study aims to test plasma exposure to PF-05089771 with same formulation will be used for phase II trials (capsule).</brief_summary>
	<brief_title>Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12lead ECG and clinical laboratory tests). Females must be of nonchildbearing potential. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). An informed consent document signed and dated by the subject or a legally acceptable representative, indicating that the subject has been informed of all pertinent aspects of the trial. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures Evidence or history of clinically significant hematological, renal (i.e recurrent uric nephrolithiasis), endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Any condition possibly affecting drug absorption (eg, gastrectomy)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>